← All trials
NCT04889040
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2021
- Primary completion
- Nov 17, 2021
- Completion date
- Nov 17, 2021
- First posted
- May 17, 2021
- Last posted
- Sep 14, 2021
- Enrollment
- 1386
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Atea Pharmaceuticals, Inc.Lead sponsor
- RocheStudy director
- RocheCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.